Upper Gastrointestinal Tract Safety of Daily Oral Risedronate in Patients Taking NSAIDs: A Randomized, Double-Blind, Placebo-Controlled Trial

Adami, Silvano; Pavelka, Karel; Cline, Gary A.; Hosterman, Mark A.; Barton, Ian P.; Cohen, Stanley B.; Bensen, William G.
October 2005
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1278
Academic Journal
OBJECTIVE: To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies. PATIENTS AND METHODS: Male and female patients aged 40 to 80 years with mild to moderate medial-compartment knee osteoarthritis were enrolled. Data were pooled and analyzed for risedronate at 5 mg and at 15 mg once daily and compared with placebo. The results of the once-weekly dosages (35 or 50 mg) were assessed separately. RESULTS: A total of 2483 patients were randomized: 622 to placebo, 628 to risedronate at 5 mg/d, 609 to risedronate at 15 mg/d, 310 to risedronate at 35 mg once weekly, and 314 to risedronate at 50 mg once weekly. During the study, 77% of patients were regular nonsteroidal anti-inflammatory drug (NSAID) and/or analgesic users (defined as those who took medication ≥3 days per week), and 68% were regular NSAID users. The number of upper GI tract adverse events was similar between treatment groups, with no dose-related response: 161 for placebo, 176 for risedronate at 5 mg/d. and 150 for risedronate at 15 mg/d. The time to the first upper GI tract adverse event was similar between treatment groups. There was no difference in the frequency of upper GI tract adverse events in risedronate-treated patients compared with patients who were regular users of NSAIDs or NSAIDs and/or analgesics. Findings were similar for those in the once-weekly risedronate groups. CONCLUSION: The results of this study show that risedronate regimens at 5 mg/d or 15 mg/d as well as once weekly at 35 mg or 50 mg are not associated with an increased frequency of upper GI tract adverse events, even in patients who have an increased risk for such events.


Related Articles

  • Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologist's Perspective. Lehmann, F. S.; Beglinger, C. // Current Topics in Medicinal Chemistry;Jun2005, Vol. 5 Issue 5, p449 

    Non-selective NSAIDs enhance the risk of serious ulcer complications (bleeding, perforation, obstruction), hospitalization and death about 3-10-fold. The gastrointestinal side effects of NSAIDs have a considerable economical burden, since they are responsible for 5-10 billion dollars in...

  • Involvement of oxidative stress in the pathogenesis of NSAID-induced gastric mucosal damage. Hiraishi, Hideyuki; Shimada, Tadahito; Terano, Akira // Journal of Gastroenterology;2000, Vol. 35 Issue 7, p567 

    Editorial. Discusses whether or not oxygen-derived free radicals from neutrophils contribute to non-steroidal anti-inflammatory drugs (NSAID)-induced gastric mucosal injury and ulceration in humans. Gastrointestinal complications of NSAID; Administration of anti-ulcer drugs with antioxidant...

  • Gastroprotection During NSAID Use. Walling, Anne D. // American Family Physician;1/15/2007, Vol. 75 Issue 2, p258 

    The article discusses research being done on gastroprotection during nonsteroidal anti-inflammatory drugs (NSAID) utilization. It references a study by L. E. Targownik and colleagues, published in the September 2006 issue of "Canadian Family Physician." It mentions the gastrointestinal...

  • Physician preference more important than patient risk.  // Reactions Weekly;4/16/2005, Issue 1047, p5 

    Discusses research being done on the importance of physician preference in determining the odds of receiving preventive strategies in combination with nonsteroidal anti-inflammatory agent (NSAID) therapy. Reference to a study by I. Francetic, M. Bilusic, M. Huie, et al, published in a 2005...

  • CSM UPDATE: Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions--2.  // British Medical Journal (Clinical Research Edition);5/3/1986, Vol. 292 Issue 6529, p1190 

    Examines the adverse reactions to non-steroidal anti-inflammatory drugs affecting the gastrointestinal tract. Data on the number of reports of serious gastrointestinal reactions; Factors contributing to the various drug reactions; Comparison between non-steroidal anti-inflammatory drugs.

  • Rofecoxib. Scott, L.J.; Lamb, H.M. // Drugs;Sep1999, Vol. 58 Issue 3, p499 

    â–´ Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1 is observed with rofecoxib up to doses of 1000mg. â–´ In 4 large double-blind randomised trials performed in patients with osteoarthritis, rofecoxib...

  • A COX-2-Specific Inhibitor Plus a Proton-Pump Inhibitor: Is This a Reasonable Approach to Reduction in NSAIDs' GI Toxicity? Cryer, Byron // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p711 

    The two prevailing approaches to decrease risks of nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal (GI) events are the use of a COX-2 inhibitor or co-therapy with a proton-pump inhibitor (PPI). A major limitation of each approach is that, in patients at the highest risk...

  • Pain-medication safety.  // Consumer Reports on Health;Nov99, Vol. 11 Issue 11, p2 

    Presents a graph showing the results of toxicity tests conducted on pain medications and nonsteroidal anti-inflammatory drugs.

  • Pharmacology of Chiral Compounds 2-Arylpropionic Acid Derivatives. Landoni, M.F.; Soraci, A. // Current Drug Metabolism;Mar2001, Vol. 2 Issue 1, p37 

    Molecules exist as three dimensional structures. Therefore they can exist in symmetrical and asymmetrical forms. Molecules with an asymmetric centre are chiral. If the molecule and its mirror image are non-superimposable, the relationship between the two molecules is enantiomeric and the two...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics